These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 20845461

  • 1. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
    Ganta S, Devalapally H, Amiji M.
    J Pharm Sci; 2010 Nov; 99(11):4630-41. PubMed ID: 20845461
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 3. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
    Ganta S, Amiji M.
    Mol Pharm; 2009 May 15; 6(3):928-39. PubMed ID: 19278222
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
    Alemi A, Zavar Reza J, Haghiralsadat F, Zarei Jaliani H, Haghi Karamallah M, Hosseini SA, Haghi Karamallah S.
    J Nanobiotechnology; 2018 Mar 23; 16(1):28. PubMed ID: 29571289
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O.
    Cancer Chemother Pharmacol; 2002 Apr 23; 49(4):322-8. PubMed ID: 11914912
    [Abstract] [Full Text] [Related]

  • 6. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
    Lee K, Chae SW, Xia Y, Kim NH, Kim HJ, Rhie S, Lee HJ.
    Eur J Pharmacol; 2014 Jan 15; 723():381-8. PubMed ID: 24252806
    [Abstract] [Full Text] [Related]

  • 7. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
    Bu H, He X, Zhang Z, Yin Q, Yu H, Li Y.
    Int J Pharm; 2014 Aug 25; 471(1-2):206-13. PubMed ID: 24866272
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
    Kim JE, Park YJ.
    Int J Nanomedicine; 2017 Aug 25; 12():645-658. PubMed ID: 28176896
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response.
    Pawar VK, Panchal SB, Singh Y, Meher JG, Sharma K, Singh P, Bora HK, Singh A, Datta D, Chourasia MK.
    J Control Release; 2014 Dec 28; 196():295-306. PubMed ID: 25459427
    [Abstract] [Full Text] [Related]

  • 10. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
    Wang X, Chen Y, Dahmani FZ, Yin L, Zhou J, Yao J.
    Biomaterials; 2014 Aug 28; 35(26):7654-65. PubMed ID: 24927684
    [Abstract] [Full Text] [Related]

  • 11. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.
    Choudhury H, Gorain B, Karmakar S, Biswas E, Dey G, Barik R, Mandal M, Pal TK.
    Int J Pharm; 2014 Jan 02; 460(1-2):131-43. PubMed ID: 24239580
    [Abstract] [Full Text] [Related]

  • 12. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.
    Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM.
    Eur J Pharm Biopharm; 2012 Aug 02; 81(3):514-23. PubMed ID: 22516136
    [Abstract] [Full Text] [Related]

  • 13. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.
    Patel K, Patil A, Mehta M, Gota V, Vavia P.
    Int J Pharm; 2014 Sep 10; 472(1-2):214-23. PubMed ID: 24954663
    [Abstract] [Full Text] [Related]

  • 14. Enhanced oral bioavailability of paclitaxel by solid dispersion granulation.
    Shanmugam S, Im HT, Sohn YT, Kim YI, Park JH, Park ES, Woo JS.
    Drug Dev Ind Pharm; 2015 Sep 10; 41(11):1864-76. PubMed ID: 25775012
    [Abstract] [Full Text] [Related]

  • 15. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
    Cai Q, Deng X, Li Z, An D, Shen T, Zhong M.
    Drug Deliv; 2016 Sep 10; 23(1):147-53. PubMed ID: 24786483
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic effects of curcumin nanoemulsions on prostate cancer.
    Guan YB, Zhou SY, Zhang YQ, Wang JL, Tian YD, Jia YY, Sun YJ.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun 10; 37(3):371-378. PubMed ID: 28585133
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
    Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H.
    Biomaterials; 2008 Mar 10; 29(9):1233-41. PubMed ID: 18093646
    [Abstract] [Full Text] [Related]

  • 18. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
    Bai F, Wang C, Lu Q, Zhao M, Ban FQ, Yu DH, Guan YY, Luan X, Liu YR, Chen HZ, Fang C.
    Biomaterials; 2013 Aug 10; 34(26):6163-74. PubMed ID: 23706689
    [Abstract] [Full Text] [Related]

  • 19. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
    Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K.
    Int J Pharm; 2011 Jun 30; 412(1-2):132-41. PubMed ID: 21507344
    [Abstract] [Full Text] [Related]

  • 20. Selective tissue distribution and long circulation endowed by paclitaxel loaded PEGylated poly(ε-caprolactone-co-L-lactide) micelles leading to improved anti-tumor effects and low systematic toxicity.
    Wang F, Shen Y, Xu X, Lv L, Li Y, Liu J, Li M, Guo A, Guo S, Jin F.
    Int J Pharm; 2013 Nov 01; 456(1):101-12. PubMed ID: 23968782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.